Zobrazeno 1 - 10
of 1 348
pro vyhledávání: '"11"'
Autor:
Francis J. Hornicek, Zhenfeng Duan, Jacson Shen, Xianzhe Liu, Henry J. Mankin, Edwin Choy, Yan Gao, Wen Yang
Publikováno v:
Molecular Cancer Therapeutics. 15:1691-1701
Ovarian cancer is currently the most lethal gynecologic malignancy with limited treatment options. Improved targeted therapies are needed to combat ovarian cancer. Here, we report the identification of cyclin-dependent kinase 11 (CDK11) as a mediator
Publikováno v:
Molecular Cancer Therapeutics. 10:1751-1759
E-cadherin is an important tumor suppressor gene whose expression is lost when cells acquire a metastatic phenotype. We analyzed the role of E-cadherin missplicing as a mechanism of its downregulation by analyzing a misspliced E-cadherin transcript t
Autor:
Oliver Zaccheo, Stuart Prince, Emily J. Foulstone, Andrew Bassim Hassan, Christopher Williams
Publikováno v:
Molecular Cancer Therapeutics. 6:607-617
Ligands transported by the mannose 6-phosphate/insulin-like growth factor (IGF)-II receptor (IGF2R) include IGF-II– and mannose 6-phosphate–modified proteins. Increased extracellular supply of IGF-II, either secondary to loss of the clearance fun
Autor:
Michele Connelly, Jia Xie, Nathaniel R. Twarog, Natasha Sahr, Jessica Gartrell, Hyekyung P. Cho, Anang A. Shelat, Sara M. Federico, Kaley Blankenship, Marcia Mellado-Largarde, Jiyang Yu, Christopher L. Tinkle, Geoffrey Neale, Elizabeth Stewart, Lauren Hoffmann, Koon-Kiu Yan, Armita Bahrami, Shondra M. Pruett-Miller, April Sykes, Michael R. Clay, Shaina N. Porter
Publikováno v:
Mol Cancer Ther
Pediatric sarcomas represent a heterogeneous group of malignancies that exhibit variable response to DNA-damaging chemotherapy. Schlafen family member 11 protein (SLFN11) increases sensitivity to replicative stress and has been implicated as a potent
Autor:
Lukas Manuel Dunkl, Chen Liu, Morvarid Mohseni, Saskia M. Brachmann, Peter S. Hammerman, Eric Billy, Jeffrey A. Engelman, Malika Kazic-Legueux, Eusebio Manchado, Giordano Caponigro, Hengyu Lu, Roberto Velazquez, Hongyun Wang, Anne Haberkorn, Susan Moody, Huai Xiang Hao
Publikováno v:
Molecular Cancer Therapeutics. 18:1323-1334
FGFR1 was recently shown to be activated as part of a compensatory response to prolonged treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic cancer cell lines. We hypothesize that other receptor tyrosine kinases (RT
Autor:
Charlène Duboc, Laurent Poulain, Marie-Hélène Louis, Edwige Abeilard, Marie Villedieu, Christophe Denoyelle, Pascal Gauduchon, Cécile Pétigny-Lechartier, Abdelghani Jebahi
Publikováno v:
Molecular Cancer Therapeutics. 16:102-115
The identification of novel therapeutic strategies is an important urgent requirement for the clinical management of ovarian cancer, which remains the leading cause of death from gynecologic cancer. Several studies have shown that the antiapoptotic p
Autor:
Shamit K. Dutta, Debabrata Mukhopadhyay, Hisato Kawakami, Shengbing Huang, Krishnendu Pal, Frank A. Sinicrope
Publikováno v:
Molecular Cancer Therapeutics. 15:3015-3027
Oncogenic BRAFV600E mutations activate MAPK signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer. In BRAFV600E-mutant colorectal cancers, treatment failure may be related to BRAFV600E-mediated a
Autor:
Yuichi Aono, Seijiro Toriyama, Yukako Morioka, Toshiyuki Sakai, Toshiya Takamura, Tsuneharu Miki, Mano Horinaka, Tomoyuki Taniguchi, Shusuke Yasuda, Osamu Ukimura
Publikováno v:
Molecular Cancer Therapeutics. 15:2066-2075
The prognosis of muscle-invasive bladder cancer with metastasis is poor. There have been no therapeutic improvements for many years, and an innovative therapy for muscle-invasive bladder cancer has been awaited to replace the conventional cytotoxic c
Autor:
Fen Liu, Jia Yu Wang, Chun Yan Wang, Xu Guang Yan, Su Tang Guo, Chen Chen Jiang, Lei Jin, Hamed Yari, Yuan Yuan Zhang, Xudong Zhang
Publikováno v:
Molecular Cancer Therapeutics. 15:448-459
Oncogenic mutations of KRAS pose a great challenge in the treatment of colorectal cancer. Here we report that mutant KRAS colon cancer cells are nevertheless more susceptible to apoptosis induced by the HSP90 inhibitor AUY922 than those carrying wild
Autor:
Hisato Kawakami, Kazuto Nishio, Kazuhiko Nakagawa, Kazuyoshi Yanagihara, Shinya Ueda, Shinichi Nishina, Wataru Okamoto, Isamu Okamoto, Takayasu Kurata, Tokuzo Arao
Publikováno v:
Molecular Cancer Therapeutics. 11:1557-1564
Therapeutic strategies that target the tyrosine kinase MET hold promise for gastric cancer, but the mechanism underlying the antitumor activity of such strategies remains unclear. We examined the antitumor action of the MET tyrosine kinase inhibitor